These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34818480)

  • 41. Comprehensive
    Karaghiannis V; Maric D; Garrec C; Maaziz N; Buffet A; Schmitt L; Antunes V; Airaud F; Aral B; Le Roy A; Corbineau S; Mansour-Hendili L; Lesieur V; Rimbert A; Laporte F; Delamare M; Rab M; Bézieau S; Cassinat B; Galacteros F; Gimenez-Roqueplo AP; Burnichon N; Cario H; Van Wijk R; Bento C; Girodon F; Hoogewijs D; Gardie B
    Haematologica; 2023 Jun; 108(6):1652-1666. PubMed ID: 36700397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
    Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
    Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An
    Wang H; Cui J; Yang C; Rosenblum JS; Zhang Q; Song Q; Pang Y; Fang F; Sun M; Dmitriev P; Gilbert MR; Eisenhofer G; Pacak K; Zhuang Z
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31091718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
    Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
    Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted Therapies in Pheochromocytoma and Paraganglioma.
    Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
    J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Translational repression of HIF2α expression in mice with Chuvash polycythemia reverses polycythemia.
    Ghosh MC; Zhang DL; Ollivierre H; Eckhaus MA; Rouault TA
    J Clin Invest; 2018 Apr; 128(4):1317-1325. PubMed ID: 29480820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease.
    Vaidya A; Flores SK; Cheng ZM; Nicolas M; Deng Y; Opotowsky AR; Lourenço DM; Barletta JA; Rana HQ; Pereira MA; Toledo RA; Dahia PLM
    N Engl J Med; 2018 Mar; 378(13):1259-1261. PubMed ID: 29601261
    [No Abstract]   [Full Text] [Related]  

  • 48. A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia.
    Yu J; Shi X; Yang C; Bullova P; Hong CS; Nesvick CL; Dmitriev P; Pacak K; Zhuang Z; Cao H; Li L
    Aging (Albany NY); 2020 Apr; 12(7):5781-5791. PubMed ID: 32235007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia.
    Yang C; Hong CS; Prchal JT; Balint MT; Pacak K; Zhuang Z
    Hum Genome Var; 2015; 2():15053. PubMed ID: 27081557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New syndrome of paraganglioma and somatostatinoma associated with polycythemia.
    Pacak K; Jochmanova I; Prodanov T; Yang C; Merino MJ; Fojo T; Prchal JT; Tischler AS; Lechan RM; Zhuang Z
    J Clin Oncol; 2013 May; 31(13):1690-8. PubMed ID: 23509317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
    Ferrara AM; Lombardi G; Pambuku A; Meringolo D; Bertorelle R; Nardin M; Schiavi F; Iacobone M; Opocher G; Zagonel V; Zovato S
    Anticancer Drugs; 2018 Jan; 29(1):102-105. PubMed ID: 29099418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
    Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2
    Pang Y; Gupta G; Yang C; Wang H; Huynh TT; Abdullaev Z; Pack SD; Percy MJ; Lappin TRJ; Zhuang Z; Pacak K
    BMC Cancer; 2018 Mar; 18(1):286. PubMed ID: 29534684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.
    Därr R; Nambuba J; Del Rivero J; Janssen I; Merino M; Todorovic M; Balint B; Jochmanova I; Prchal JT; Lechan RM; Tischler AS; Popovic V; Miljic D; Adams KT; Prall FR; Ling A; Golomb MR; Ferguson M; Nilubol N; Chen CC; Chew E; Taïeb D; Stratakis CA; Fojo T; Yang C; Kebebew E; Zhuang Z; Pacak K
    Endocr Relat Cancer; 2016 Dec; 23(12):899-908. PubMed ID: 27679736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
    Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic Analysis of Pheochromocytoma and Paraganglioma Complicating Cyanotic Congenital Heart Disease.
    Ogasawara T; Fujii Y; Kakiuchi N; Shiozawa Y; Sakamoto R; Ogawa Y; Ootani K; Ito E; Tanaka T; Watanabe K; Yoshida Y; Kimura N; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2545-2555. PubMed ID: 35730597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
    Bausch B; Schiavi F; Ni Y; Welander J; Patocs A; Ngeow J; Wellner U; Malinoc A; Taschin E; Barbon G; Lanza V; Söderkvist P; Stenman A; Larsson C; Svahn F; Chen JL; Marquard J; Fraenkel M; Walter MA; Peczkowska M; Prejbisz A; Jarzab B; Hasse-Lazar K; Petersenn S; Moeller LC; Meyer A; Reisch N; Trupka A; Brase C; Galiano M; Preuss SF; Kwok P; Lendvai N; Berisha G; Makay Ö; Boedeker CC; Weryha G; Racz K; Januszewicz A; Walz MK; Gimm O; Opocher G; Eng C; Neumann HPH;
    JAMA Oncol; 2017 Sep; 3(9):1204-1212. PubMed ID: 28384794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma.
    Karakaya S; Gunnesson L; Elias E; Martos-Salvo P; Robledo M; Nilsson O; Wängberg B; Abel F; Påhlman S; Muth A; Mohlin S
    Sci Rep; 2023 Jul; 13(1):11588. PubMed ID: 37463949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gain-of-function mutations in DNMT3A in patients with paraganglioma.
    Remacha L; Currás-Freixes M; Torres-Ruiz R; Schiavi F; Torres-Pérez R; Calsina B; Letón R; Comino-Méndez I; Roldán-Romero JM; Montero-Conde C; Santos M; Pérez LI; Pita G; Alonso MR; Honrado E; Pedrinaci S; Crespo-Facorro B; Percesepe A; Falcioni M; Rodríguez-Perales S; Korpershoek E; Ramón-Maiques S; Opocher G; Rodríguez-Antona C; Robledo M; Cascón A
    Genet Med; 2018 Dec; 20(12):1644-1651. PubMed ID: 29740169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.